140.98
-1.84 (-1.29%)
| Previous Close | 142.82 |
| Open | 142.42 |
| Volume | 1,566,058 |
| Avg. Volume (3M) | 2,353,791 |
| Market Cap | 30,430,834,688 |
| Price / Sales | 50.81 |
| Price / Book | 45.22 |
| 52 Weeks Range | |
| Earnings Date | 7 May 2026 |
| Profit Margin | -265.93% |
| Operating Margin (TTM) | -247.61% |
| Diluted EPS (TTM) | -5.93 |
| Quarterly Revenue Growth (YOY) | 22.90% |
| Total Debt/Equity (MRQ) | 1,316.96% |
| Current Ratio (MRQ) | 5.86 |
| Operating Cash Flow (TTM) | -761.93 M |
| Levered Free Cash Flow (TTM) | -480.63 M |
| Return on Assets (TTM) | -36.25% |
| Return on Equity (TTM) | -890.75% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | Insmed Incorporated | Bearish | Bullish |
AIStockmoo Score
| Analyst Consensus | 1.0 |
| Insider Activity | -1.5 |
| Price Volatility | 2.0 |
| Technical Moving Averages | 1.0 |
| Technical Oscillators | -0.5 |
| Average | 0.40 |
|
Insmed Inc is a global biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the US for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. The company's earlier-stage clinical pipeline includes Brensocatib, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases; and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for pulmonary arterial hypertension. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Mid Growth |
| % Held by Insiders | 0.75% |
| % Held by Institutions | 110.72% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 231.00 (Barclays, 63.85%) | Buy |
| Median | 210.00 (48.96%) | |
| Low | 162.00 (Morgan Stanley, 14.91%) | Hold |
| Average | 207.83 (47.42%) | |
| Total | 5 Buy, 1 Hold | |
| Avg. Price @ Call | 158.59 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Mizuho | 24 Feb 2026 | 204.00 (44.70%) | Buy | 158.62 |
| HC Wainwright & Co. | 23 Feb 2026 | 230.00 (63.14%) | Buy | 159.03 |
| Wells Fargo | 20 Feb 2026 | 208.00 (47.54%) | Buy | 164.91 |
| Morgan Stanley | 30 Jan 2026 | 162.00 (14.91%) | Hold | 156.87 |
| Barclays | 28 Jan 2026 | 231.00 (63.85%) | Buy | 155.89 |
| Roth Capital | 23 Jan 2026 | 212.00 (50.38%) | Buy | 156.21 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| LEWIS WILLIAM | - | 142.79 | -10,699 | -1,527,710 |
| Aggregate Net Quantity | -10,699 | |||
| Aggregate Net Value ($) | -1,527,710 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 142.79 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| LEWIS WILLIAM | Officer | 16 Apr 2026 | Automatic sell (-) | 10,699 | 142.79 | 1,527,710 |
| LEWIS WILLIAM | Officer | 16 Apr 2026 | Option execute | 10,699 | - | - |
| Date | Type | Details |
|---|---|---|
| 05 Feb 2026 | Announcement | Insmed to Host Fourth-Quarter and Full-Year 2025 Financial Results Conference Call on Thursday, February 19, 2026 |
| 28 Jan 2026 | Announcement | Insmed to Present Multiple Abstracts on Treprostinil Palmitil Inhalation Powder (TPIP) at Pulmonary Vascular Research Institute (PVRI) 2026 Congress |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |